Retatrutide

Packaging reference. Confirm the selected size and supplied label.
Retatrutide is an investigational peptide studied for weight loss and blood sugar control. It activates three hormone receptors involved in metabolism, called GLP-1, GIP and glucagon. That’s why you’ll see it called a triple agonist.
Multi-vial savings: Mix eligible vials. Save automatically.
For laboratory research only. Not for human or veterinary use.
The compound, clearly explained
What is Retatrutide?
Retatrutide is known as a triple-receptor agonist. In plain language, it activates three types of receptors involved in metabolic signalling: GLP-1, GIP and glucagon. That three-target approach is what sets it apart in comparisons with semaglutide and tirzepatide.
Explore the Retatrutide research profile →Know the material
Specifications
Categories: Weight & Metabolism
Additional information
| Size | 5 mg, 10 mg, 20 mg |
|---|
Exact size. Exact lot.
Batch & COA
Select a package size to view documentation for that exact SKU.
Research & references
What is Retatrutide?
Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP and glucagon. Researchers are studying how activating all three affects body weight and blood sugar. Separate trials have measured outcomes such as sleep apnoea.
A receptor is a structure on a cell that responds to a signal. An agonist activates it. GLP-1 and GIP are involved in blood sugar regulation, and GLP-1 also plays a role in appetite signalling. Glucagon helps regulate how the body manages glucose and energy. Retatrutide activates receptors for all three.
What did the studies find?
Phase 2 obesity trial
In a randomised study of 338 adults, the highest trial group had an estimated average weight reduction of 24.2% at 48 weeks, compared with 2.1% with placebo. Weight change at 48 weeks was a secondary outcome. Digestive side effects were common and generally increased with dose. Researchers also observed a dose-dependent rise in heart rate that peaked at 24 weeks and then declined.
TRIUMPH-1 · Adults without diabetes
The Phase 3 trial reported greater average weight loss with retatrutide than with placebo at 80 weeks. Read the trial for the different analyses, adverse events and discontinuations.
TRIUMPH-2 · Adults with type 2 diabetes
At 80 weeks, average weight changed by −18.8% in the highest trial group and −5.1% with placebo in the treatment-regimen analysis. Blood sugar control also improved. Digestive side effects were more common in the retatrutide groups. The participants in this trial had type 2 diabetes, which is an important distinction when comparing studies.
Read TRIUMPH-2 · Read the sleep apnoea studies
Reading trial results
Start with who enrolled, what the researchers measured and when they measured it. Body weight, blood sugar, body composition and appetite are different outcomes. Check whether the analysis includes participants who stopped treatment. Trial results describe the preparation and study population the researchers tested. The catalogue vial has its own material specification and batch documentation.
Read the research in context
Reading the Phase 2 and Phase 3 numbers together
The trials use different follow-up periods and include different populations. In particular, a group without diabetes and a group with type 2 diabetes are not directly comparable. Check the eligibility criteria, which outcome the trial prioritised and how researchers treated withdrawals in the analysis.
The 48-week Phase 2 result and the 80-week Phase 3 result answer separate questions. Use each result alongside its placebo group and study conditions. Digestive side effects, heart-rate observations and discontinuations also help explain what was seen in each study.
Three receptors and what they tell you
GLP-1, GIP and glucagon receptors participate in metabolic signalling. The triple-agonist description identifies the pathways the compound activates. It does not tell you the size of a weight change or rank it against a different molecule. Those comparisons require outcome data and an appropriate study design.
Read the product specification and batch report together
Start with the product name, size and lot number. The product specification describes the supplied material and the amount listed on the label. A certificate of analysis, often called a COA, records what a lab found in a particular sample. Match the lot number before using any test result. When the listing has multiple sizes, check that the document applies to the selected size or explains why the same report covers more than one option.
Identity, purity and measured content are separate questions. An identity test checks which material the lab detected. A purity figure depends on the method and what that method measures. Measured content is a quantitative result and should state its units and basis. A result expressed as a percentage of chromatographic peak area does not tell you the milligrams present in a vial. Look for a separate content result if the amount matters to your work.
Keep a copy of the specification and matching report with your research records. If a field is important and the report does not give it, ask for the specific detail. For work that depends on storage temperature or stability, request the written conditions for the supplied form and lot. A reference paper may describe how its authors handled a different preparation, which is a separate record.
How to read a peptide COA · Peptide purity versus measured content · Peptide Place quality standards · Browse published lab results
Related product records: Tirzepatide · Semaglutide 5 mg. For background and original sources, browse the Research Library or the peptide comparison guides.
A practical reading order
Start with the Phase 2 paper for the early study design and the Phase 3 papers for the later populations. Read the trial comparison by follow-up time, participant criteria and analysis. Keep side effects and discontinuations alongside the primary outcome.
Studies and further reading
Retatrutide vial options
Choose 5 mg, 10 mg or 20 mg to see the price and availability for that option. The listed milligrams are the nominal amount in the vial.
Specifications and batch documentation
Reference chemistry and identity details
| Nominal vial options | 5 mg, 10 mg and 20 mg |
|---|---|
| Research synonym | LY3437943 |
| Research class | Peptide studied as a GLP-1, GIP and glucagon receptor agonist |
| Exact sequence and modifications | Supplier confirmation pending |
| Formula and expected mass | Supplier confirmation pending |
| Formulation and content basis | Supplier confirmation pending |
Retatrutide is also known by the research code LY3437943. For the supplied material, check the form, counterion and basis used for the nominal amount. Reference chemistry describes the molecule. The material specification and matching certificate of analysis describe the selected option and sample.
Match the compound, size and lot before relying on a report. Read identity, chromatographic purity and measured content as separate results. If you have a question about batch documentation, include the lot number from your vial.
Browse lab results · How to read a COA
Storage and laboratory handling
Use the documented conditions for the supplied material and lot. Keep the label and record the lot and date received. Ask for the written specification if your work depends on a particular temperature or stability window.
Laboratory storage and handling guide
Retatrutide research profile · Weight & Metabolism research
Explore this topic further
Compare the compound first
Composition & comparisons
Retatrutide vs semaglutide vs tirzepatide
- Semaglutide activates the GLP-1 receptor.
- Tirzepatide activates GIP and GLP-1 receptors.
- Retatrutide activates GIP, GLP-1 and glucagon receptors.
Receptor activity explains how the molecules differ. Weight changes from separate trials depend on the participants, study duration and analysis. A head-to-head study would compare the compounds under the same conditions.
Compare related materials
Useful answers
Your questions about Retatrutide
What does triple agonist mean?
One compound activates three receptor types. For retatrutide those are GIP, GLP-1 and glucagon.
What is LY3437943?
It is a research identifier for retatrutide.
What did the Phase 2 study find?
The highest trial group had an estimated average weight reduction of 24.2% at 48 weeks, compared with 2.1% with placebo.
What did TRIUMPH-2 study?
It studied adults with type 2 diabetes and obesity or overweight. The study measured weight and blood sugar outcomes and reported adverse events.
How does retatrutide differ from tirzepatide?
Both activate GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor.
What does 10 mg mean on the vial?
It is the nominal amount listed for that option. A separate quantitative result is needed to verify measured content.
Which vial sizes are listed?
The catalogue lists 5 mg, 10 mg and 20 mg. Select a size to see current availability.
Does a larger vial change the molecule?
The size changes the nominal amount in the package. Check the product specification to confirm the supplied form.
Do clinical papers verify the catalogue material?
Clinical papers describe their own study preparation. Check the specification and batch documentation for the vial you have.
Where is the matching lot report?
Select the exact size, then check the linked batch record. If no certificate is published, ask for the matching source report. A report for another size or lot is not evidence for this one.
Does a vial amount equal measured peptide content?
Not necessarily. The package amount is the listing specification. Check whether the source certificate separately reports measured content, and read its units and basis. Chromatographic purity is not a content assay.
Where are salt form and storage conditions listed?
Use the supplier-confirmed specifications for the material and lot. Reference chemistry does not confirm the supplied salt, terminal form or handling conditions. Contact Peptide Place if a required field is not documented.
How do Canadian shipping and payment work?
Pay by Interac e-Transfer using the order instructions. Shipping is tracked Canada Post Xpresspost: $18.99 below $199, or free from $199 after discounts and before tax. Transit timing depends on the destination and current carrier conditions.
Do you provide personal-use instructions?
No. These products are supplied for laboratory research only, not for human or veterinary use. Vial quantities do not describe a recommended dose.
Does targeting three receptors explain how it compares with two?
Receptor count describes the mechanism. Compare outcomes only after checking whether the studies recruited similar groups and used similar follow-up, analysis and comparators.
What should I include in a documentation question?
Send the product name, the selected size and the lot number if you have it. If you need a specific result, such as identity or measured content, mention that too so we can help you find the right document.
Continue your research
Related research compounds
- Weight & Metabolism

MOTS-c
Mitochondrial peptide research on cellular energy and metabolic regulation.
From $79.99In stock
- Growth Hormone

Tesamorelin
Growth hormone and abdominal-fat research, with the study population explained.
From $109.99In stock
A question before you order?
Help with product information, documentation or an existing order.

